Adult GlioblastomaPhase 1NCT04573140Papers
Autologous total tumor mRNA
RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)
What the film says
The youngest children with brain tumors face a hard trade: radiation damages a growing brain, so doctors use intensive chemotherapy instead, and many relapse anyway.
The idea: after standard treatment, send in T cells trained on that child's own tumor.
At Children's National, a piece of the tumor removed at surgery is sequenced and its proteins read to find markers unique to that cancer. The child's T cells are then grown in the lab against several of those markers at once, without gene editing, and infused once therapy is complete.
An early safety study, for children under five with embryonal tumors, and recurrent ependymoma up to age thirty.
Brian Rood leads IMPACT in Washington. Public record; not medical advice.
Sources behind this film
Young children cannot receive irradiation; intensive chemo + stem cell rescue; many relapse; TSA-T generated after standard-of-care / salvage therapy; Proteogenomically determined tumor-specific antigens from the patient's primary tumor tissue; Multi-antigen, non-gene-modified cytotoxic T lymphocytes ("without gene editing") (+2 more lines)
The drug
Participants in this study will receive TSA-T after completion of standard-of-care treatment.
Patients will undergo surgical resection, then be treated with standard-of-care therapy as required, which may include up to 3 induction chemotherapy cycles (vincristine, cyclophosphamide, cisplatin, etoposide with or without methotrexate) and up to 3 consolidation cycles (carboplatin and thiotepa, each followed by an infusion of autologous peripheral blood stem cells).
TSA-T products will be manufactured at the cell therapy Good Manufacturing Practice (GMP) facility at Children's National Hospital (CNH). Patients enrolled in the study will receive their infusions at CNH.
The study
This is an open-label phase 1 safety and feasibility study that will employ multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized tumor-specific antigens (TSA) derived from a patient's primary brain tumor tissues.
Young patients with embryonal central nervous system (CNS) malignancies typically are unable to receive irradiation due to significant adverse effects and are treated with intensive chemotherapy followed by autologous stem cell rescue; however, despite intensive therapy, many of these patients relapse.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.